Sight Diagnostics raises $71 million for blood-testing computer vision

This more than doubles the startup's total raised, and a spokesperson says it will be used to accelerate Sight's operations globally -- with a focus on the U.S. -- as Sight advances R&D for the detection of conditions like sepsis and cancer, as well as factors affecting COVID-19. Blood tests are generally unpleasant -- not to mention costly. On average, getting blood work done at a lab costs uninsured patients between $100 and $1,500. In the developing world, where the requisite equipment isn't always readily available, ancillary costs threaten to drive the price substantially higher. That's why Yossi Pollak, previously at Intel subsidiary Mobileye, and Daniel Levner, a former scientist at Harvard's Wyss Institute for Biologically Inspired Engineering, founded Sight Diagnostics in 2011.